GenSight Biologics S.A.: GenSight Biologics Confirms Sustain

Sustained efficacy three years after injection: statistically significant visual acuity improvement from nadir Continuous benefits in bilaterally treated patients with +17 to +20 ETDRS letters

Related Keywords

United States , Paris , France General , France , Italy , Taiwan , United Kingdom , Spain , Dennis Riedl , James Palmer , Gensight Biologics Euronext , Guillaume Van Renterghem , Nancyj Newman , Jeanene Timberlake , Gensight Biologics , Bernard Gilly , Thomas Gidoin , International Principal Investigator , European Union , European Medicines Agency , Emory University School Of Medicine Atlanta , Best Corrected Visual Acuity , Business Wire , Sight Biologics , Emory University School , Special Protocol Assessment , Leber Hereditary Optic Neuropathy , Sight Biologic , Mitochondrial Targeting Sequence , Gensight Biologic , Hereditary Optic Neuropathy , Institut De La Vision , Adeno Associated Virus , Financial Officer , Gensight , Iologics , Onfirms , Sustained , Efficacy , Safety , Bilateral , Umevoq , Injections , Ear , Follow , Reflect , Hase , Trial ,